NEW YORK (GenomeWeb News) - Agilent Technologies and Integrated DNA Technologies will jointly offer oligo synthesis and other products and services to create a "complete development pathway" for drug developers, the companies said yesterday.
 
The companies said they will provide reciprocal referrals for synthetic oligonucleotides and will offer chemical and analytical services designed to help customers reduce time and costs associated with moving from research to clinical development.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.